A multidisciplinary panel of Italian experts has concluded that IgM-enriched polyclonal intravenous immunoglobulin (IVIg) therapy is appropriate for specific clinical phenotypes in critically ill patients with sepsis, provided standard care is optimized. Published in the Journal of Anesthesia, Analgesia and Critical Care, this consensus report represents a structured effort to navigate the complex landscape of immunomodulatory adjunctive therapies, where previous interventions have largely failed to demonstrate consistent clinical efficacy. The study utilized a modified RAND/UCLA Appropriateness Method to systematically evaluate the use of IVIg across seven predefined clinical scenarios, aiming to deliver pragmatic, phenotype-oriented guidance for intensive care practitioners.
The rationale for this consensus stems from the observation that low circulating immunoglobulin levels are common in septic patients and are consistently associated with greater disease severity and poorer outcomes. While no immunomodulatory intervention has yet shown definitive clinical efficacy in unselected sepsis populations, the biological plausibility of targeting specific immune phenotypes remains strong. The expert panel, comprising 19 specialists in intensive care medicine, infectious diseases, transplant medicine, and oncology, sought to integrate current evidence with clinical judgment to identify subgroups where IgM-enriched preparations might offer a targeted benefit.
The methodology involved a structured literature review of PubMed, EMBASE, and the Cochrane Library, followed by anonymous voting by 21 panelists using a 9-point Likert scale. Indications were classified as appropriate (median score 7–9), uncertain (median score 4–6), or inappropriate (median score 1–3). The panel evaluated seven distinct phenotypes identified as clinically relevant and extensively addressed in the available literature, including severe community-acquired pneumonia, abdominal infections, sepsis in solid-organ transplant recipients, overwhelming septic shock, post-cardiac surgery sepsis, multidrug-resistant pathogen sepsis, and haematologic malignancies.
In the context of severe community-acquired pneumonia (sCAP), the consensus rated IVIg use as appropriate when accompanied by shock, low IgM levels below 60 mg/dL, or a history of immunosuppression, with median scores of 8 for each scenario. Conversely, the appropriateness of IVIg for sCAP with hyperinflammation but without shock was rated as uncertain, with a median score of 6. This distinction highlights the panel’s focus on the severity of the inflammatory response and the presence of circulatory compromise as key determinants for adjunctive therapy.
For abdominal infections, the panel judged IVIg appropriate in patients with endotoxaemic shock, immune suppression or paralysis, or low IgM levels, all receiving a median score of 8. The biological rationale centers on the role of endotoxins as principal mediators of organ dysfunction in intra-abdominal infections. Immunoglobulins, particularly IgM, are proposed to neutralize endotoxins, enhance complement deposition on pathogens, and facilitate efficient phagocytosis, thereby limiting infection-induced tissue injury and preventing excessive inflammation.
In solid-organ transplant recipients, IVIg was rated appropriate for treating sepsis, particularly when low IgM levels were present, with median scores of 7 and 8, respectively. However, the prophylactic use of IVIg to prevent infections in high-risk transplant recipients was rated as uncertain, with a median score of 5. This uncertainty reflects the heterogeneous evidence regarding prophylaxis, where benefits have been observed in heart transplant recipients with hypogammaglobulinaemia but not consistently in lung or intestinal transplant recipients.
The consensus strongly supported the use of IgM-enriched IVIg in overwhelming septic shock with severe hyperinflammation, assigning a median score of 8. This rating rose to 9 for toxin-mediated syndromes, such as invasive meningococcal diseases or necrotising fasciitis, where immunoglobulins act as potent scavengers of pathogens and toxins. The panel also rated IVIg appropriate for post-cardiac surgery sepsis with signs of immune suppression (median 7), but uncertain for hyperinflammation alone (median 6), acknowledging the complex interplay between surgical trauma-induced inflammation and subsequent immunosuppression.
For sepsis caused by multidrug-resistant (MDR) pathogens, IVIg was rated appropriate when combined with signs of immune suppression, with median scores ranging from 7 to 8 depending on the presence of low immunoglobulin levels. The rationale includes the potential of IgM to enhance the efficacy of antibiotics by improving opsonisation and bacterial clearance, a strategy that may be particularly beneficial when antibiotic penetration is limited or resistance is high. In haematologic malignancies, IVIg was rated appropriate for treating sepsis, especially when immunoglobulin levels are low, while prophylaxis was generally rated as uncertain.
Across all evaluated phenotypes, the panel consistently preferred IgM-enriched preparations over standard IVIg, with median scores ranging from 8 to 9. This preference is grounded in the unique structural and functional properties of IgM, which enhance bacterial phagocytosis, promote bacterial lysis, and modulate dendritic cell function. The consensus emphasizes that these preparations should be considered as adjunctive strategies to optimize standard care, rather than as standalone treatments.
The available evidence suggests that IVIg therapy, including IgM-enriched preparations, does not present major safety signals in septic patients, although adverse events are likely to be underreported due to the critical nature of the underlying illness. The consensus underscores that while biological plausibility and expert judgment support the phenotype-based use of IVIg, significant evidence gaps remain. The authors stress the need for adequately powered, well-designed clinical trials to define optimal timing, dosing, and responsive patient subgroups, as current international guidelines provide only a weak recommendation against routine use in unselected patients.
The consensus pathway began in March 2025 when two moderators convened nineteen Italian specialists to outline the clinical scope and identify patient subsets characterized by high mortality and profound immune dysregulation. The moderators selected panel members based on recognized clinical and scientific experience in managing sepsis within intensive care units. Designated experts performed systematic literature searches across PubMed, EMBASE, and the Cochrane Library, summarizing available evidence ahead of a second meeting in July 2025 to refine the proposed clinical questions. Formal rating occurred in November 2025 through an anonymous online platform where twenty-one panel members evaluated each statement on a 9-point Likert scale. Indication status was derived from median scores, while panel consensus was evaluated using the Interpercentile Range Adjusted for Symmetry without subsequent voting rounds. The authors noted that this initiative was funded by an unrestricted grant from Grifols, which had no influence over question development, voting, data interpretation, or manuscript composition, and formal ethics approval was not required because the analysis utilized expert ratings rather than individual patient records.
In addressing pulmonary and abdominal conditions, the experts weighed specific biological markers and trial observations. For severe community-acquired pneumonia, the panel considered evidence from a phase II randomized trial demonstrating that early administration of an enriched formulation in patients requiring mechanical ventilation increased ventilator-free days, achieving a median of 14.0 days compared to 4.0 days for placebo among those presenting with marked hyperinflammation. Pharmacodynamic analyses indicated that this intervention modulated systemic inflammatory markers, including procalcitonin and C-reactive protein, while altering absolute neutrophil and lymphocyte counts. In intra-abdominal infections, where gut barrier compromise promotes bacterial and endotoxin translocation, circulating endotoxin activity correlates directly with progressive multiorgan failure. The panel reviewed data from a placebo-controlled trial of sixty-four abdominal sepsis patients comparing an IgM- and IgA-enriched preparation with albumin; although the reduction in mechanical ventilation duration fell short of statistical significance, the treated cohort experienced reduced fever, lower tumor necrosis factor-alpha levels, faster procalcitonin decline, and an increase in platelets, indicating measurable biological modulation.
The consensus elaborated on overwhelming septic shock by distinguishing it from general vasopressor dependence through the presence of abrupt, massive cytokine release, including tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, and interferon-gamma. These surges promote vasoplegia, endothelial permeability, and myocardial depression in patients who already require high-dose vasopressor support exceeding standard clinical thresholds. In reviewing hyperinflammatory and toxin-mediated conditions, the experts noted historical trials in streptococcal toxic shock syndrome reporting shorter times to shock reversal and lower twenty-eight-day mortality, alongside data in invasive meningococcal disease showing improved survival and fewer permanent neurological sequelae following adjuvant IgM-enriched therapy. Parallel considerations emerged for sepsis following cardiac surgery, a complication affecting between 0.39 and 2.5 percent of operative cases and carrying mortality rates between 65 and 79 percent. Cardiopulmonary bypass circuits, surgical tissue trauma, and reperfusion injury drive early systemic inflammation and subsequent immunosuppression; in this setting, observational studies showed that pairing IgM-enriched immunoglobulins with extracorporeal blood purification lowered inflammatory mediators and improved sequential organ failure assessment scores, while retrospective analyses identified survival gains specifically among patients with severe sepsis.
Concerning resistant bacterial infections and haematological malignancies, the document highlighted critical immune mechanisms and ongoing prospective evaluations. Against multidrug-resistant Gram-negative bacteria such as Acinetobacter, Klebsiella, and Pseudomonas, pentameric IgM provides superior bacterial agglutination and complement activation compared with IgG preparations, with retrospective evaluations of approximately three hundred ICU patients in Italy and Greece reporting a 20 percent reduction in mortality. In haematological disease, where sepsis incidence is fifteen times greater than in the general population and mortality approaches 60 percent, guidelines support replacement therapy at 0.4 grams per kilogram to keep IgG above 400 milligrams per deciliter following allogeneic stem cell transplantation or cellular therapy. While an earlier randomized trial in neutropenic patients showed no mortality benefit from IgM-enriched therapy, preliminary findings from an ongoing multicenter clinical trial investigating early adjuvant IgM-enriched immunoglobulin in patients colonized by carbapenem-resistant pathogens who experience febrile neutropenia indicate improved infection control and lower mortality at thirty days and four months.
Subject of Research: Expert consensus on the phenotype-based appropriateness of IgM-enriched IVIg in critical illness
Article Title: Phenotype-based appropriateness of IGM-enriched polyclonal immunoglobulin use in critical illness: report of an expert consensus
Article References: Coloretti, I., Bignami, E. G., Busani, S., Clerici, D., Corcione, A., Corona, A., Donati, A., De Pascale, G., De Rosa, F. G., Forfori, F., Grasso, S., Imperatore, F., Montrucchio, G., Mornese, P. S., Pognuz, E. R., Rubulotta, M. F., Paternoster, G., Pellis, T., Siniscalchi, A., … Girardis, M. (2026). Phenotype-based appropriateness of IGM-enriched polyclonal immunoglobulin use in critical illness: report of an expert consensus. Journal of Anesthesia, Analgesia and Critical Care, 6(1), Article 126. https://doi.org/10.1186/s44158-026-00459-8
Image Credits: AI Generated
DOI: 10.1186/s44158-026-00459-8
Keywords: IgM-enriched IVIg, Sepsis management, Expert consensus, RAND/UCLA Appropriateness Method, Community-acquired pneumonia, Abdominal infections, Solid-organ transplantation, Septic shock, Multidrug-resistant pathogens, Haematologic malignancies, Immunomodulatory therapy, Critical care medicine, Phenotype-based treatment, Intravenous immunoglobulin, Endotoxaemia, Post-cardiac surgery sepsis, Hypogammaglobulinaemia, Clinical appropriateness, Journal of Anesthesia, Analgesia and Critical Care, Italian expert panel
News Source: Ophelia Keating. (November 18, 2026). Italian experts rate IgM-enriched IVIg appropriate for specific sepsis phenotypes. Scienmag.



